Last reviewed · How we verify
Dual antiplatelet agent duration
Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events.
Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events. Used for Acute coronary syndrome with percutaneous coronary intervention, Stable coronary artery disease with stent placement, Secondary prevention of myocardial infarction and stent thrombosis.
At a glance
| Generic name | Dual antiplatelet agent duration |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Antiplatelet agent combination |
| Target | Cyclooxygenase (COX) and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Dual antiplatelet agent therapy typically combines aspirin (which inhibits cyclooxygenase and thromboxane A2 production) with a P2Y12 receptor antagonist (such as clopidogrel, prasugrel, or ticagrelor) to provide synergistic antiplatelet effects. This combination is more effective at preventing stent thrombosis and recurrent ischemic events than monotherapy, though it increases bleeding risk. The duration of therapy is tailored based on clinical context, balancing ischemic and bleeding risks.
Approved indications
- Acute coronary syndrome with percutaneous coronary intervention
- Stable coronary artery disease with stent placement
- Secondary prevention of myocardial infarction and stent thrombosis
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
Key clinical trials
- Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (PHASE3)
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) (PHASE3)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
- Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD) (NA)
- Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling (PHASE4)
- HOST - DAPT Duration According the Bleeding Risk (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |